MX2010006125A - Utilizacion de alfa-1-antitripsina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica. - Google Patents
Utilizacion de alfa-1-antitripsina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica.Info
- Publication number
- MX2010006125A MX2010006125A MX2010006125A MX2010006125A MX2010006125A MX 2010006125 A MX2010006125 A MX 2010006125A MX 2010006125 A MX2010006125 A MX 2010006125A MX 2010006125 A MX2010006125 A MX 2010006125A MX 2010006125 A MX2010006125 A MX 2010006125A
- Authority
- MX
- Mexico
- Prior art keywords
- alpha
- antitrypsin
- aat
- cfs
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/56—Protease inhibitors from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Botany (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Nutrition Science (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200930387A ES2332645B1 (es) | 2009-06-30 | 2009-06-30 | Utilizacion de alfa-1-antitripsina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010006125A true MX2010006125A (es) | 2011-01-05 |
Family
ID=41571181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010006125A MX2010006125A (es) | 2009-06-30 | 2010-06-03 | Utilizacion de alfa-1-antitripsina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9205134B2 (https=) |
| EP (1) | EP2289540B1 (https=) |
| JP (1) | JP5231490B2 (https=) |
| CN (1) | CN101934071B (https=) |
| AR (1) | AR077123A1 (https=) |
| AU (1) | AU2010202203B2 (https=) |
| BR (1) | BRPI1002087B1 (https=) |
| CA (1) | CA2706212C (https=) |
| CL (1) | CL2010000575A1 (https=) |
| ES (2) | ES2332645B1 (https=) |
| MX (1) | MX2010006125A (https=) |
| NZ (1) | NZ585890A (https=) |
| PL (1) | PL2289540T3 (https=) |
| PT (1) | PT2289540E (https=) |
| RU (1) | RU2436590C1 (https=) |
| UY (1) | UY32670A (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014014751A8 (pt) * | 2011-12-19 | 2017-07-04 | Lfb Usa Inc | composição compreendendo alfa-1-antitripsina, células epiteliais de glândula mamária, mamífero não humano transgênico, e, método para reduzir a atividade de elastase no pulmão |
| US10034921B2 (en) | 2013-02-13 | 2018-07-31 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Proteins with modified glycosylation and methods of production thereof |
| US20220160847A1 (en) * | 2020-11-20 | 2022-05-26 | Mark Egly | Method of preventing and/or treating a plurality of diseases |
| WO2023184473A1 (zh) * | 2022-04-01 | 2023-10-05 | 首创生物技术有限公司 | 肽用于治疗神经退行性疾病或改善认知功能的用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2281222A (en) * | 1941-09-27 | 1942-04-28 | American Bosch Corp | Speed regulator for internal combustion engines |
| US5753624A (en) * | 1990-04-27 | 1998-05-19 | Milkhaus Laboratory, Inc. | Materials and methods for treatment of plaquing disease |
| EP0584185B1 (en) * | 1991-05-14 | 1999-08-11 | Ernir Snorrason | Treatment of fatigue syndrome with cholinesterase inhibitors |
| WO2000051623A2 (en) | 1999-03-05 | 2000-09-08 | The Trustees Of University Technology Corporation | Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions |
| WO2001081343A2 (en) * | 2000-04-21 | 2001-11-01 | Pharmacia & Upjohn Company | Compounds for treating fibromyalgia and chronic fatigue syndrome |
| WO2002006837A1 (en) * | 2000-07-14 | 2002-01-24 | Matsushita Electric Industrial Co., Ltd. | Particle-labeled protein and immuno-chromatograph using the same |
| AU2003286258B2 (en) | 2002-11-20 | 2006-12-21 | Arriva-Prometic Inc. | Composition and method for treating inflammatory diseases using protease inhibitors |
| US7344882B2 (en) * | 2003-05-12 | 2008-03-18 | Bristol-Myers Squibb Company | Polynucleotides encoding variants of the TRP channel family member, LTRPC3 |
| US7850970B2 (en) * | 2003-08-26 | 2010-12-14 | The Regents Of The University Of Colorado | Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections |
| WO2006026837A1 (en) * | 2004-09-07 | 2006-03-16 | Patrick Englebienne | Diagnostic methods for measuring elastase activity levels |
| ES2281222B1 (es) | 2004-09-24 | 2008-06-01 | Grifols, S.A. | Utilizacion de alfa-1 antitripsina para la preparacion de medicamentos para el tratamiento de la fibromialgia. |
| EP2114141A2 (en) * | 2007-01-10 | 2009-11-11 | University of Florida | Compounds and methods for treatment of alpha-1 antitrypsin deficiency |
| MX2010003113A (es) * | 2007-09-25 | 2010-04-01 | Abbott Lab | Compuestos de octahidropentaleno como antagonistas del receptor de quimiocina. |
| HUE030205T2 (en) | 2007-11-02 | 2017-05-29 | Grifols Therapeutics Inc | A method, composition, and product for providing alpha-1-antitrypsin |
-
2009
- 2009-06-30 ES ES200930387A patent/ES2332645B1/es not_active Expired - Fee Related
-
2010
- 2010-05-20 ES ES10380071T patent/ES2392691T3/es active Active
- 2010-05-20 PT PT103800710T patent/PT2289540E/pt unknown
- 2010-05-20 EP EP10380071A patent/EP2289540B1/en active Active
- 2010-05-20 PL PL10380071T patent/PL2289540T3/pl unknown
- 2010-05-27 UY UY0001032670A patent/UY32670A/es not_active Application Discontinuation
- 2010-05-28 AU AU2010202203A patent/AU2010202203B2/en active Active
- 2010-06-02 NZ NZ585890A patent/NZ585890A/en not_active IP Right Cessation
- 2010-06-02 CL CL2010000575A patent/CL2010000575A1/es unknown
- 2010-06-03 MX MX2010006125A patent/MX2010006125A/es active IP Right Grant
- 2010-06-04 CA CA2706212A patent/CA2706212C/en active Active
- 2010-06-17 AR ARP100102142A patent/AR077123A1/es unknown
- 2010-06-24 BR BRPI1002087-0A patent/BRPI1002087B1/pt not_active IP Right Cessation
- 2010-06-24 US US12/822,764 patent/US9205134B2/en active Active
- 2010-06-29 JP JP2010147994A patent/JP5231490B2/ja active Active
- 2010-06-29 RU RU2010126653/15A patent/RU2436590C1/ru active
- 2010-06-30 CN CN2010102168418A patent/CN101934071B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| NZ585890A (en) | 2011-11-25 |
| AR077123A1 (es) | 2011-08-03 |
| AU2010202203A1 (en) | 2011-01-20 |
| CL2010000575A1 (es) | 2011-10-28 |
| US9205134B2 (en) | 2015-12-08 |
| US20100331261A1 (en) | 2010-12-30 |
| CA2706212C (en) | 2014-02-04 |
| BRPI1002087A2 (pt) | 2012-03-13 |
| EP2289540B1 (en) | 2012-08-22 |
| AU2010202203B2 (en) | 2012-08-23 |
| EP2289540A1 (en) | 2011-03-02 |
| ES2332645B1 (es) | 2010-10-18 |
| PL2289540T3 (pl) | 2013-03-29 |
| ES2392691T3 (es) | 2012-12-12 |
| CN101934071B (zh) | 2012-11-28 |
| CN101934071A (zh) | 2011-01-05 |
| JP2011012060A (ja) | 2011-01-20 |
| UY32670A (es) | 2011-01-31 |
| BRPI1002087B1 (pt) | 2019-07-02 |
| CA2706212A1 (en) | 2010-12-30 |
| RU2436590C1 (ru) | 2011-12-20 |
| HK1148198A1 (en) | 2011-09-02 |
| PT2289540E (pt) | 2012-12-04 |
| JP5231490B2 (ja) | 2013-07-10 |
| ES2332645A1 (es) | 2010-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mazzuca et al. | Immunological and homeostatic pathways of alpha-1 antitrypsin: a new therapeutic potential | |
| MX2010006125A (es) | Utilizacion de alfa-1-antitripsina para la preparacion de medicamentos para el tratamiento del sindrome de fatiga cronica. | |
| CN115089698A (zh) | 改善皮肤的活性肽与干细胞外泌体在药品或化妆品中的应用 | |
| EP3533455A1 (en) | Inhibition of proteolytic activity in the treatment of mitochondriopathies | |
| Opoku et al. | Fibroblast Growth Factor–21 ameliorates hepatic encephalopathy by activating the STAT3-SOCS3 pathway to inhibit activated hepatic stellate cells | |
| CN103649106B (zh) | 用于治疗神经退行性和缺血性脑疾病的化合物和药学组合 | |
| Lu et al. | Calycosin attenuates Angiostrongylus cantonensis-induced parasitic meningitis through modulation of HO-1 and NF-κB activation | |
| KR101556812B1 (ko) | 하부 요로 질환 치료제 및 하부 요로 증상 개선제 | |
| CN114983922A (zh) | 生物活性肽与干细胞外泌体在皮肤修复中的应用 | |
| AU2016217473B2 (en) | Thymosin alpha 1 for use in treatment of cystic fibrosis | |
| KR20080098488A (ko) | Ｈｉｖ 치료 | |
| US20060067913A1 (en) | HCV therapy | |
| US12454549B2 (en) | Treatments for diseases and disorders that involve oxidative stress | |
| HK1148198B (en) | Use of alpha-1-antitrypsin for the preparation of drugs for the treatment of chronic fatigue syndrome | |
| Jain | Neuroprotection in Miscellaneous Neurological Disorders | |
| WO2019008015A1 (en) | GAS MIXTURES CONTAINING XENON AND LOW CONCENTRATION ARGON AS AN ORGAN PROTECTIVE AGENT, IN PARTICULAR A NEUROPROTECTIVE | |
| WO2023239716A2 (en) | Treatments for diseases and disorders that involve oxidative stress | |
| Savoldelli et al. | PB1987 SELECTIVE ACTIVATION OF TOLEROGENIC CELL DEATH PATHWAYS IN MESENCHYMAL STROMAL CELLS | |
| Sriram | Neuroimmune interaction of TGFβ1 and TGFβ2 | |
| Humphries et al. | We-PL3: 3 Can candidate gene genotypes improve estimation of CHD risk over-and above conventional risk factors in healthy UK men? | |
| KR20210060574A (ko) | 응고 이상을 수반하는 패혈증의 치료 및/또는 개선을 위한 의약 | |
| Wewers | Dyspnea and Cirrhosis | |
| Matsuzawa | We-PL3: 1 Adipocytokines: Emerging therapeutic target for metabolic syndrome | |
| Verlag | Meeting Report IBC's 2nd International Conference on Protease Inhibitors: Novel Therapeutic Applications and Development, Washington DC, USA, 24-26 February 1997 | |
| Ferizi et al. | Psoriasis in child in our clinic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |